Introduction
============

Long-term exposure to ambient fine particulate matter (≤ 2.5 μg/m^3^ in aerodynamic diameter; PM~2.5~) is associated with increased mortality from nonaccidental and cause-specific diseases ([@r4]; [@r8]; [@r9]; [@r13]). Epidemiologic cohort studies, conducted largely in the United States, have reported this association for annual ambient average concentrations from approximately 5 to 30 μg/m^3^, although definitive knowledge of which specific sources or characteristics of PM~2.5~ are responsible for these associations is currently lacking \[[@r41]; [@r42], [@r43]\]. No epidemiologic study, however, has estimated the association of long-term exposure to direct measurements of PM~2.5~ with mortality from chronic cardiovascular and respiratory disease at the higher ambient exposures common in cities and other areas in Asia and other developing countries where annual average exposures can exceed 100 μg/m^3^ ([@r3]; [@r12]). As a result, estimates of disease burden attributable to ambient air pollution in these locations have had to be based on extrapolations of the results of epidemiologic studies from locations with lower ambient PM~2.5~ exposures ([@r1]; [@r7]; [@r11]).

Previous efforts to estimate global burden from exposure to ambient air pollution (AAP) in the form of PM~2.5~ postulated risk functions for cardiopulmonary mortality as linearly increasing in relative risk (RR) from 7.5 to 50 μg/m^3^, with no further change in RR at higher concentrations ([@r7]). Sensitivity analyses included a model in which RR varied as the logarithm of concentration, producing a more gradual diminution of the marginal increase in RR than the base case model. The logarithmic model was subsequently recommended by the WHO for use in air pollution burden of disease estimates at the national level ([@r30]). The coefficients of these models were based on information from a single U.S. cohort study---the American Cancer Society Cancer Prevention Study II (CPS-II) ([@r13]; [@r34])---with exposure assignments of \< 22 μg/m^3^. The form of the models used for global burden assessment was motivated largely by the concern that linear extrapolation using these coefficients would produce unrealistically large estimates of RR compared with other known PM~2.5~-related mortality risks such as active smoking (AS) and exposure to secondhand tobacco smoke (SHS) ([@r7]; [@r30]). These RR models were also employed in more recent estimates of global mortality associated with ambient PM~2.5~ concentrations ([@r1]; [@r11]).

Absent empirical epidemiologic evidence on the magnitude of the association with mortality at high exposures of PM~2.5~ in ambient environments, [@r35] suggested that the integration of epidemiologic evidence on cardiovascular and lung cancer (LC) mortality RR from disparate types of PM~2.5~ exposure such as AAP, SHS, and AS, may provide insight into the shape of the exposure--response relation over a much wider range of exposures.

Here we present the methodology used to estimate the population attributable fraction (PAF) from exposure to ambient PM~2.5~ in the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (the GBD 2010 project) ([@r14]). We selected a mathematical form of the RR function with a PM~2.5~ concentration that could describe the observed relationships between RR and exposure for the five outcomes examined. We fit this model for cause-specific adult mortality for four causes of death---ischemic heart disease (IHD), stroke, chronic obstructive pulmonary disease (COPD), and LC---using RR information from epidemiologic studies of long-term exposure to particulate matter not only from AAP, SHS, and AS, but also from studies of household air pollution from solid cookfuel (household air pollution; HAP). We used these models to estimate the percentage of PAF associated with exposure to ambient PM~2.5~ for each of the 187 countries included in the GBD 2010 project. We identified a specific model form that best predicts source-specific RR for all four causes of death. In addition, we examined the relationship between PM~2.5~ exposure and the incidence of acute lower respiratory infection (ALRI) in infants, another health outcome considered in the GBD 2010 project. Because infants and young children are non(active)-smokers, the largest PM~2.5~ exposures considered for ALRI are from HAP.

Methods
=======

*Underlying assumptions*. The model we propose in here was based on the following underlying assumptions:

1.  Exposure to PM~2.5~ from diverse combustion sources is associated with increased mortality from IHD, stroke, COPD, and LC and with increased incidence of ALRI. This assumption is based on systematic review of the available epidemiologic literature conducted by the GBD 2010 Ambient Air Pollution Expert Group as part of the GBD 2010 project ([@r14]).

2.  The observed RRs from AAP, SHS, HAP, and AS are a function of PM~2.5~ mass inhaled concentration across all combustion particle sources ([@r37]). The toxicity of PM~2.5~ is assumed to differ only with regard to inhaled mass (exposure) and not with PM~2.5~ composition. The toxicity of emissions from different combustion sources may well differ, but current knowledge does not allow definitive and quantifiable conclusions regarding their relative toxicity and little is known about international variation in source contributions around the world ([@r40]; [@r41]; [@r42]).

3.  The relation between PM~2.5~ exposure and excess mortality RR is not necessarily restricted to a linear function over the range of human exposure to PM~2.5~ from diverse sources ([@r33], [@r35]).

4.  The RR of mortality from chronic disease experienced by people exposed to AAP, SHS, HAP, and AS is a function of long-term, cumulative exposure quantified in terms of daily average exposure concentration and does not depend on the temporal pattern of exposure ([@r32], [@r35]). This assumption is required because the temporal nature of PM~2.5~ exposure differs for AAP, SHS, HAP, and AS.

5.  The RR associated with each type of exposure does not depend on the other types of exposure. That is, we are assuming no interaction among the different exposure types for any cause of mortality. We are aware of no empirical epidemiologic evidence that tests that assumption; however, the direct epidemiologic evidence from the cohort studies we used to estimate the burden attributable to ambient PM~2.5~ shows that active cigarette smokers are also affected adversely by exposure to ambient PM~2.5~, and these studies do not provide support for significant heterogeneity of the relative excess AAP RR across smoking categories.

*Model form*. We selected a mathematical form of an integrated exposure--response (IER) model that could describe several patterns in RR thought to be *a priori* applicable to exposure--response models. We wanted the IER to be able to take shapes similar to models previously used for burden assessment, such as linear and log-linear ([@r7]) and a power function ([@r33], [@r35]). In addition to these shapes, we also required the IER to have a property that it flattens out at high exposures, consistent with evidence of the relationship between IHD mortality and smoking intensity ([@r33]).

The form must equal 1 when PM~2.5~ values are below some concentration that represents a counterfactual low exposure where below this level there is no excess risk. We also desired a model that increases monotonically with increasing PM~2.5~ exposure concentration and could take a variety of shapes, such as near linear, sublinear, and supralinear. Our IER model has the following form:

for *z* \< *z~cf~*, *RR*~IER~(*z*) = 1

for *z* ≥ *z~cf~*, *RR*~IER~(*z*) = 1 + α {1 -- exp\[-- γ (*z -- z~cf~*)^δ^\]}, \[1\]

where *z* is the exposure to PM~2.5~ in micrograms per meter cubed and *z~cf~* is the counterfactual concentration below which we assumed there is no additional risk. For very large *z*, *RR*~IER~ approximates 1 + α. We included a power of PM~2.5~, δ, to predict risk over a very large range of concentrations. Further, *RR*~IER~ (*z~cf~* + 1) approximates 1 + αγ. Thus, γ = \[*RR*~IER~ (*z~cf~* + 1) -- 1\]/\[*RR*~IER~ (∞) -- 1\] can be interpreted as the ratio of the RR at low-to-high exposures. We term our model an "integrated-exposure response" model because its development requires the integration of exposures to PM~2.5~ from different combustion types (i.e., AAP, SHS, HAP, and AS).

In formulating our RR model, we relied on information on the RR of mortality at specified PM~2.5~ exposure concentrations from the available literature. Suppose we have a set of RR estimates {^\^^*r~1~*^(^*^s^*^)^,...,^\^^*r~Ks~*^(^*^s^*^)^, *s =* 1*,...,S*} and corresponding confidence intervals (CIs) based on PM~2.5~ concentrations {*z~1~*^(^*^s^*^)^,...,*z~Ks~*^(^*^s^*^)^, *s* = 1,...,*S*}, for S different types of PM~2.5~ sources, where *K~s~* is the number of RR estimates available from for source type S. The unknown parameters (α, γ, δ) are estimated by nonlinear regression methods. We then weighted the RR estimates by the inverse of the variance estimate of the logarithm of the RR in order to reflect the uncertainties in each estimate.

We compared the IER model to seven other models that have been previously suggested for burden assessment. These include an RR model that is linear in exposure throughout the global concentration range (Lin), a model that is linear up to 30 μg/m^3^ and constant above 30 μg/m^3^ (Lin30), a model that is linear up to 50 μg/m^3^ and constant above 50 μg/m^3^ (Lin50), and a model that is a function of the logarithm of exposure (Log). These models were used in a previous assessment of global burden of disease due to AAP exposure ([@r7]). We also postulated a model in which we added an unknown parameter to concentration in the Log model to allow more flexibility in fitting the type-specific RRs (Log2). The sixth model examined related RR to a power of exposure as proposed by [@r33], [@r35]), with the seventh model equivalent to the IER with δ = 1(Exp). For the mathematical forms of the models, see the Supplemental Material (Sensitivity of RRs and PAFs to Model Form, pp. 9--11). We then calculated both the Akaike and Bayesian information criteria (AIC, BIC) for each of the eight models examined and five health outcomes as measures of goodness of fit.

The method of constructing uncertainty bounds on model predictions is described in detail in the Supplemental Material (Characterizing Uncertainty, pp. 28--29). Briefly, we simulated 1,000 sets of source type--specific RRs based on their point estimates and CIs and fit the IER model to these simulated values, obtaining 1,000 sets of parameter estimates of (α,γ,δ). Using these parameter estimates, we then generated 1,000 IER functions over the global concentration range. Estimates of uncertainty were also generated for the PM~2.5~ concentrations. Uncertainty in the PAFs is a function of the uncertainty in the IER model predictions and the exposure estimates and is determined by simulation methods as described in the Supplemental Material (Characterizing Uncertainty, pp. 28--29).

Specifics of the selection of source type--specific RR and PM~2.5~ exposure for each type are described below for the four mortality outcomes. The logarithm of the RR per micrograms per meter cubed, its SE, and associated PM~2.5~ concentration for the five outcomes is given by type of PM~2.5~ in Supplemental Material, Table S1.

*AAP*. To fit the risk models, we used cause-specific mortality AAP RR estimates from available published cohort studies. We evaluated each RR estimate at its study-specific PM~2.5~ mean concentration minus a less-polluted counterfactual level ([@r14]). Most RRs were obtained from published reports; however, in some cases new analyses were conducted for the present study. These estimates are identified in Supplemental Material, Table S1. We had eight studies reporting RR estimates for IHD mortality, five for stroke mortality, three for COPD mortality, and four for LC mortality.

*SHS*. We selected RRs for both IHD (8 studies reporting separate estimates for males and females) and LC (46 studies) mortality from studies included in the U.S. Surgeon General's Report, *The Health Consequences of Involuntary Exposure to Tobacco Smoke* ([@r18]). We associated the RR of death due to SHS exposure with an equivalent ambient PM~2.5~ concentration of 20 μg/m^3^ for low-to-moderate SHS exposure and 50 μg/m^3^ for moderate-to-high exposure based on the analysis of [@r33] for IHD mortality because RRs were reported by the [@r18] for these two descriptive exposure categories. We assigned a concentration of 35 μg/m^3^ based on the midpoint of the range 20--50 μg/m^3^ for LC mortality because no specific description of the level of SHS exposure was provided by the [@r18]. We selected 29 RRs from studies examined by [@r19] for stroke mortality on the basis of prospective cohort studies with an associated PM~2.5~ concentration of 35 μg/m^3^. There was insufficient evidence to estimate a RR due to SHS exposure for COPD mortality. We assumed that the SHS RRs are associated with a change in PM~2.5~ exposure based on nonsmoking subjects living with a smoker compared with those not living with a smoker. We have not incorporated other potential sources of PM~2.5~ exposure for these study subjects, such as from indoor sources, near-roadway conditions, or occupational exposures by subject.

*AS*. Following [@r33], [@r35]), we estimated the RR of each of the four causes of death for current cigarettes smoked per day compared with never smokers from the CPS-II. We estimated the RR and 95% CIs associated with 10 cigarettes-per-day groupings: 1--3, 4--7, 8--12, 13--17, 18--22, 23--27, 28--32, 33--37, 38--42, and \> 42 cigarettes/day. We estimated that smoking a single cigarette was equivalent to breathing a daily ambient concentration of PM~2.5~ of 667 μg/m^3^, assuming an average breathing rate of 18 m^3^/day and an inhaled dose of 12,000 μg PM~2.5~ mass per cigarette ([@r33]). We then estimated the equivalent ambient concentration of PM~2.5~ by multiplying the average cigarettes/day smoked in each interval by 667 μg/m^3^. The shape of the curve fitted by [@r33], [@r35]) was not sensitive to the estimate of equivalent ambient PM~2.5~ concentrations for AS.

*HAP*. [@r38] conducted a meta-analysis of studies examining COPD and LC incidence rates among men and women exposed to air pollution from burning coal or biomass for cooking. There were no studies relating IHD or stroke mortality or incidence to HAP at the time of the GBD 2010 project analyses, and thus this PM~2.5~ type cannot contribute to the fit of our RR function. The equivalent long-term PM~2.5~ exposure from HAP was estimated for study subjects using coal or biomass for cooking ([@r2]) and for those study subjects using cleaner fuels to integrate this information into our IER risk model. PM~2.5~ exposure estimates for women (300 μg/m^3^) were higher than for men (200 μg/m^3^). For the COPD meta-analysis, the relevant female control group was assumed to be using a mixture of gas and chimney stoves (an estimated PM~2.5~ exposure of 100 μg/m^3^). The PM~2.5~ exposure for males was estimated to be 65% of that for females (65 μg/m^3^). For LC, the female control group was assumed to be using only gas stoves with an estimated PM~2.5~ exposure of 70 μg/m^3^. For males, the exposure was again assumed to be 65% of females, resulting in an equivalent exposure of 45.5 μg/m^3^. The meta-analytic summary risk estimate for male COPD incidence in association with HAP PM~2.5~ was 1.90 (95% CI: 1.56, 2.32) and for females was 2.70 (95% CI: 1.95, 3.75). For LC incidence among males, the summary risk estimate was 1.26 (95% CI: 1.04, 1.52) and among females was 1.81 (95% CI: 1.07, 3.06).

The lower exposure estimates in the HAP studies are substantially higher than counterfactual exposure due to the nearby use of less clean fuels; therefore, these RRs are not directly comparable to those obtained from AAP, SHS, or AS types compared with either the counterfactual (i.e., AAP) or a 0-μg/m^3^ exposure (i.e., SHS, AS). This information was included in the curve-fitting process by equating the observed RRs to the ratio of the IER model evaluated at the respective two PM~2.5~ concentrations.

The HAP studies estimated effects on incidence rather than mortality. For building the IER, we assumed that the RRs of mortality and incidence are equal.

*Age-modification risk models for IHD and stroke mortality*. Epidemiologic studies of risk factors for both IHD and stroke indicate that the RR declines with the logarithm of age, reaching 1 between 100 and 120 years of age ([@r36]). We thus modified the type-specific RR for both IHD and stroke mortality using a linear regression model of the logarithm of the median age at death for each study with the intercept equal to 1 at 110 years of age. The slope of the regression line was estimated from a meta-analysis of several risk factors ([@r36]). We applied this age-modification to the RRs and fit the IER model for each age group separately.

*Selecting the counterfactual exposure*. For each risk factor examined in the GBD 2010 project ([@r14]), the distribution of exposure was compared with an alternative (counterfactual) distribution termed the theoretical-minimum-risk exposure distribution (TMRED). For AAP, zero exposure is not a practical counterfactual level because it is impossible to achieve even in pristine environments ([@r3]). Furthermore, the lowest level of exposure to PM~2.5~ that is deemed beneficial has not been clearly identified. Defining the TMRED was based on two criteria ([@r14]): *a*) the availability of convincing evidence from epidemiologic studies that support a continuous reduction in risk of disease to the chosen distribution, and *b*) a distribution that is theoretically possible at the population level.

[@r14] suggested that a positive counterfactual concentration be used. Their counterfactual concentration is bounded by the minimum concentrations observed in the studies used to estimate risk and some low percentile of the PM~2.5~ distribution. There is clearly no evidence of an association below observed levels, and it is impractical to estimate the shape of the curve at the extremes of the exposure distribution. [@r14] suggested that the fifth percentile be used and that the lower and upper bounds on the counterfactual concentration be determined by the corresponding minimum and fifth percentiles, respectively, of the AAP PM~2.5~ exposure distribution for the CPS II cohort ([@r13]), the largest cohort study of air pollution. The minimum was 5.8 μg/m^3^ and the fifth percentile was 8.8 μg/m^3^. Uncertainty in the counterfactual concentration was modeled as a uniform distribution between the minimum and fifth percentile.

*Estimation of PAF*. We estimated the PAF associated with ambient PM~2.5~ exposure for all 187 countries separately for 2005. We first estimated surface PM~2.5~ concentrations on a 0.1° × 0.1° grid for the globe using a combination of remote sensing and atmospheric models calibrated to ground monitoring data ([@r3]). For each grid cell within a given country, we estimated the RR based on the IER model at the estimated PM~2.5~ concentration. We then constructed a population-weighted average RR for each country using the corresponding population count 0.1° × 0.1° grid cell ([@r3]). Both the gridded PM~2.5~ and population values can be obtained from [@r3]. The country-specific PAF = 1 -- 1/*WRR*~IER~, where *WRR*~IER~ is the population-weighted average of the *RR*~IER~ values at each PM~2.5~ grid cell within the country.

*IER model for ALRI*. [@r16] reviewed the evidence for an association between exposure to ambient PM~2.5~ and ALRI. Four cohort studies were deemed appropriate to include in an IER model ([@r16]). We included 23 studies of parental SHS and ALRI reported by the [@r18] with each study-specific odds ratio (OR) assigned a PM~2.5~-equivalent ambient exposure of 50 μg/m^3^, assuming a moderate-to-high level of exposure. [@r39] examined the relationship between exposure to carbon monoxide (CO) from the burning of solid biomass for heating and cooking and the incidence of ALRI in Guatemala and reported incidence rates by decile average of CO personal exposures. These decile CO averages were converted to PM~2.5~ concentrations using the following equation:

PM~2.5~(mg/m^--3^) = 0.10(0.093, 0.12) × CO(mg/m^--3^) + 0.067 (0.0069, 0.13), \[2\]

with 95% CIs displayed in parenthesis ([@r17]). This equation had good predictive power (*R*^2^ = 0.76).

Incidence rates, *I*(*z~i~*), corresponding to the 10 decile values of PM~2.5~, denoted by *z~i~* for 1 = 1,...10, can be compared with the risk model by taking the ratio of incidence rates for all unique pairs of PM~2.5~ deciles, a total of 45 pairs, and equating them to the ratio of the corresponding risk model evaluated at the appropriate decile average. That is,

*RR*~ALRI~(*z~i~, z~j~*) = *I*(*z~i~*)/*I*(*z~j~*) = \[1 + α{1 -- exp\[--γ (*z~i~ -- z~cf~*)^δ^\]}\]  ÷ \[1 + α{1 -- exp\[--γ (*z~j~ -- z~cf~*)^δ^\]}\] \[3\]

for all 45 unique pairs of concentrations (*z~i~, z~j~*), ∀*i* \> *j* = 1,...10. The 45 incidence rate ratios were combined with the 4 AAP cohort study ORs and the 23 SHS ORs in order to fit the IER model for ALRI. We assumed the same counterfactual uncertainty distribution as with the mortality IER models.

Results
=======

The average of the *RR*~IER~ predictions among the simulations are displayed for the four causes of death in [Figure 1](#f1){ref-type="fig"} in addition to the 95% CI and the type-specific RR estimates and corresponding 95% CIs used to fit the curves. The HAP RRs for COPD and LC are presented for males and females in [Figure 1](#f1){ref-type="fig"} as pink-shaded boxes with the height of each box representing the uncertainty in the RR estimates and the width representing the exposure contrast at which the RRs was assumed to pertain. Each box is centered at the RR estimate and the midpoint of the two exposure values. This alternate depiction of the HAP information was necessary because the lowest exposure levels were substantially higher than the counterfactual exposure and, therefore, not directly comparable to the RRs from the other sources. The pooled estimate of RR and its corresponding CI for SHS is displayed in placed of the study-specific SHS RRs for each unique PM~2.5~ value because the study-specific RRs and CI could not be visually distinguished. Results are presented similarly for ALRI in [Figure 2](#f2){ref-type="fig"}. In addition to the RR, the incidence of ALRI is also displayed on the right-hand *y*-axis.

![Predicted values of IER model (solid line) and 95% CIs (dashed line) and type-specific RRs (points) and 95% CIs (error bars) for IHD (*A*), stroke (*B*), COPD (*C*), and LC (*D*) mortality. Shaded boxes for COPD and LC mortality represent uncertainty (height) and exposure contrast (width) of RR HAP estimates for males (smaller boxes) and females (larger boxes) separately.](ehp.1307049.g001){#f1}

![Predicted values of IER model (solid line) and 95% CIs (dashed line) and type-specific RRs (points) and 95% CIs (error bars) for ALRI in infants.](ehp.1307049.g002){#f2}

The *RR*~IER~ function fits well the RRs for all types of PM~2.5~ and causes of mortality, except for COPD and HAP, in which the IER model underestimates the observed RRs ([Figure 1](#f1){ref-type="fig"}). This may be due to the use of the ratio of incidence rates rather than RR based on mortality data for this outcome. However, the IER curve fits the LC incidence data reasonably well. The time between diagnosis of COPD and mortality is much longer than that for LC, and thus the LC incidence data may better reflect mortality patterns than the COPD incidence data.

We compared the country-specific estimated PAFs using the age-modified models to those models using age-independent data. Age-modified *RR*~IER~ curves are displayed for IHD and stroke mortality in Supplemental Material, Figure S15 (top panels), with generally decreasing risk with increasing age. The country-specific PAFs based on risk models not modified by age and those in which age-modification models were used for both IHD and stroke mortality are presented in Supplemental Material, Figure S15 (bottom panels). Incorporating age-modification risk models tends to slightly decrease the PAF estimates.

The distribution of population-weighted country-average PM~2.5~ concentrations and PAFs are displayed in [Figure 3](#f3){ref-type="fig"}. The country average PM~2.5~ concentrations ranged from 2--70 μg/m^3^ for 2005 ([Figure 3A](#f3){ref-type="fig"}), whereas the country-level PAFs were \< 0.4 for ALRI, IHD, and stroke and \< 0.25 for LC and 0.2 for COPD ([Figure 3B](#f3){ref-type="fig"}).

![Density plots of country-specific, population-weighted PM~2.5~ concentrations (μg/m^3^) (*A*) and PAFs (*B*) by risk model and health outcome. Dashed lines represent smooth fit of density function.](ehp.1307049.g003){#f3}

Plots similar to [Figures 1](#f1){ref-type="fig"} and [2](#f2){ref-type="fig"} are displayed for the other seven model forms examined in Supplemental Material, Figures S1--S14 for both the four causes of death (Figures S1--S7) and ALRI (Figures S8--S14). In addition, both the AICs and BICs are given in Supplemental Material, Table S2, for all eight models and five outcomes. The IER model was a better predictor of the type-specific RRs than the other seven models examined for ALRI and three of the four causes of death. For COPD mortality, the Power model provided a better fit than the IER model on the basis of lower AIC and BIC values (see Supplemental Material, Table S2). This was likely due to the better prediction of the HAP RR, for which the IER model clearly underestimated the RR. Graphical comparisons of the predicted values to the type-specific RRs in Supplemental Material, Figures S1--S14, verify the conclusions drawn from the AIC/BIC results.

Discussion
==========

Exposure to PM~2.5~ in ambient air has been linked to an increased risk of death from chronic cardiovascular and respiratory disease and LC in cohort studies in the United States and Europe ([@r6]; [@r41]). Unfortunately, few long-term cohort studies have been reported for these diseases in other regions such as East and South Asia and the Middle East, where ambient exposures are much higher and where the relative contribution of specific sources of air pollution differ from those in North America and Europe ([@r3]; Heath Effects Institute 2010).

To derive the shape of the exposure--response curve at higher ambient concentrations, we incorporated information on risk due to exposure to SHS, HAP, and AS in order to extend the risk estimates to higher exposures. The IER model combines information on mortality RR from separate types of combustion, unified by equating the delivered dose from all types in terms of equivalent ambient PM~2.5~ exposures. Although we assumed that the toxicity of PM~2.5~ exposure, as characterized by RR, changes with the magnitude of exposure, we also assumed that at any fixed exposure level, toxicity is roughly equivalent among all types and temporal patterns of PM~2.5~ exposure. These are important assumptions because estimated PM~2.5~ exposure throughout the world, whether from ambient origin or household indoor combustion, has not been differentiated by the components or sources of fine particulate matter.

Only evidence from multiple epidemiologic studies of long-term exposure to PM~2.5~ in highly polluted settings can provide definitive estimates of the shape of the exposure--response function for mortality from chronic cardiovascular and respiratory diseases. However, these are starting to appear. For example, [@r5] reported an increased risk of mortality from cardiovascular and respiratory disease and LC associated with long-term exposure to total suspended particulates (TSPs) in 71,000 residents of 31 Chinese cities. Their study offers an opportunity to assess the ability of our *RR*~IER~ model to estimate the observed RRs in situations with very high levels of outdoor air pollution. In order to estimate PM~2.5~ RRs in the cohort, the authors used a 3:1 ratio to convert TSP to PM~2.5~, based on current and historical Chinese data ([@r5]). Estimated PM~2.5~ (converted from TSP) concentrations ranged among cities from 38 to 166 μg/m^3^. Increases of 2.1% (95% CI: --0.3%, 4.6%), 3.3% (95% CI: 0.9%, 5.4%), and 3.3% (95% CI: --0.3%, 6.9%) in IHD, stroke, and LC mortality, respectively, were associated with a 10-μg/m^3^ change in estimated equivalent PM~2.5~ exposures in this cohort (Kan H, personal communication).

Because the cohort members did not experience exposures near the lowest concentrations applicable to our RR model (i.e., the counterfactual concentration), we cannot determine RRs estimated from the cohort and directly compare them to our RR model, which is relative to a much lower counterfactual concentration. However, we can determine RR between concentrations observed in the cohort itself. We first determined the mean of the four quartiles of PM~2.5~ concentrations as 40, 91, 106, and 127 μg/m^3^, respectively (Kan H, personal communication) and calculated the RR between consecutive quartile averages assuming the exponential risk model form as was used by the study authors. The geometric average of these three RRs was then determined as a summary measure of change in risk over the PM~2.5~ exposure distribution. A similar calculation was undertaken for the *RR*~IER~ model. The RRs observed in the Chinese cohort and those predicted by *RR*~IER~ were similar for the three causes of death examined \[IHD: China RR = 1.06 (95% CI: 0.99, 1.14) and IER RR = 1.05 (95% CI: 1.03, 1.1); stroke: China RR = 1.10 (95% CI: 1.03, 1.17) and IER RR = 1.08 (95% CI: 1.01, 1.14; LC: China RR = 1.10 (95% CI: 0.99, 1.22) and IER RR = 1.09 (95% CI: 1.06, 1.12)\], suggesting that our IER model yielded reasonable predictions in the change in risk over a range of concentrations that prevail in China and other highly polluted settings that were not observed in cohort studies conducted in North America and Western Europe.

There are, however, some limitations in this comparison. First, TSP was a poorer predictor of cardiovascular mortality than PM~2.5~ in U.S.-based cohort studies ([@r34]). Second, uncertainty about the temporal and spatial consistency of the TSP/PM~2.5~ conversion ratio of 3:1 added uncertainty to our interpretation of the results from the Chinese cohort.

Additional uncertainties are due to a lack of information on actual exposure to PM~2.5~ for some source-specific RRs used to fit the model, notably *a*) scarce information on actual exposure from SHS in the relevant epidemiologic studies ([@r33], [@r35]), which required the estimation of PM~2.5~ concentrations from other studies; *b*) potential misclassification of exposure for SHS estimates due to possible co-exposure from AAP of the exposed group; and *c*) the duration of exposure, which differs when it comes to exposures from AAP, SHS, HAP, and AS---the lifetime duration of exposure in AS may be much shorter than in the other exposures and the received doses may, therefore, not be proportional to concentrations according to type of exposure. Uncertainties may be reduced by improving precision in the actual exposure estimates of the RRs from the epidemiologic literature used for developing the proposed model.

Multiple studies were used to estimate RRs associated with exposure to AAP, SHS, and HAP. For AS, we estimated RRs for active cigarette smokers from a single cohort, the CPS II. This cohort was also used in the GBD 2010 project to estimate risk specifically for AS ([@r14]). However, the pattern of the association between the number of cigarettes smoked per day and cause-specific mortality observed in the CPS-II cohort may not reflect the patterns observed in other cohort studies of AS (e.g., [@r31]). Similarly, the IER for ALRI is fit through RR from studies of AAP and SHS conducted in a limited number of mostly high-income countries, and a single developing country RR estimate for HAP PM~2.5~ exposure and ALRI ([@r39]). We thus recommend that future work on the IER function include additional sensitivity analyses of the type-specific RRs to which the curve is fit. Future work could also include the uncertainty in the estimate of PM~2.5~ from CO and new information in this relationship ([@r15]).

The key assumptions that underlie the IER, discussed above, largely serve to justify the integration of risk estimates for different types of PM exposure. These assumptions, and their tenability, have been addressed elsewhere ([@r33], [@r32], [@r35]). Unfortunately, for several of the most critical assumptions, those concerning the relative toxicity per unit mass of PM~2.5~ of different types (e.g., AAP and AS), not accounting for the temporal pattern of exposure, and the absence of interaction among types of combustion, there is little empirical evidence against which to evaluate those assumptions or to evaluate in detail specific implications of their violation. Each warrants additional research.

Although we set the counterfactual concentration to be drawn from a uniform distribution with a lower bound of 5.8 μg/m^3^ and an upper bound of 8.8 μg/m^3^, we are not suggesting that there is convincing evidence that PM~2.5~ mortality and ALRI risk is zero below any specific concentration based on biological considerations ([@r4]). Absence of such evidence from epidemiologic studies does not necessarily imply evidence of the absence of such a counterfactual concentration. We thus take the conservative approach and set a positive counterfactual concentration. However, our approach can be adapted to a different counterfactual if new evidence supporting a positive association at lower concentrations becomes available. One such piece of evidence was observed in Canada, where positive associations as low as 2 μg/m^3^ were noted ([@r10]).

The Lin50 and Log models proposed by [@r7] were used for the previous GBD estimates, and the Log model is currently recommended by the WHO ([@r30]). However, the unknown parameters in these models were estimated from a single cohort study of AAP, the CPS-II, which required analysis of the original data. The IER model uses RR estimates available in the open literature, allowing periodic updating of risk functions based on systematic review of the literature, and it does not require analyses of primary data not in the public domain. As new epidemiologic studies and evidence on type-specific PM~2.5~ exposure appear, the models can be reestimated by any interested member of the scientific community using publically available information.

Conclusion
==========

Fine particulate mass--based RR models can be developed that cover the entire global range of ambient exposure to PM~2.5~ by integrating RR information from different combustion sources that generate emissions of particulate matter. The specific RR model form we identified in the present study can provide superior predictive power for leading global causes of mortality for air pollution compared with a range of alternative model forms.
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=====================

###### 

Click here for additional data file.
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